BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21348561)

  • 1. Part D coverage gap and adherence to diabetes medications.
    Gu Q; Zeng F; Patel BV; Tripoli LC
    Am J Manag Care; 2010; 16(12):911-8. PubMed ID: 21348561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
    Hansen RA; Farley JF; Droege M; Maciejewski ML
    Clin Ther; 2010 Jul; 32(7):1308-19. PubMed ID: 20678679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of Medicare Part D on medication adherence among older adults enrolled in Medicare-Advantage products.
    Zhang Y; Lave JR; Donohue JM; Fischer MA; Chernew ME; Newhouse JP
    Med Care; 2010 May; 48(5):409-17. PubMed ID: 20393360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional variation in use of a new class of antidiabetic medication among medicare beneficiaries: the case of incretin mimetics.
    Marcum ZA; Driessen J; Thorpe CT; Donohue JM; Gellad WF
    Ann Pharmacother; 2015 Mar; 49(3):285-92. PubMed ID: 25515869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy.
    Barner JC
    Clin Ther; 2011 Sep; 33(9):1281-8. PubMed ID: 21840054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying the impact of drug exposure misclassification due to restrictive drug coverage in administrative databases: a simulation cohort study.
    Gamble JM; McAlister FA; Johnson JA; Eurich DT
    Value Health; 2012 Jan; 15(1):191-7. PubMed ID: 22264988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative adherence to diabetes drugs: An analysis of electronic health records and claims data.
    Flory J; Gerhard T; Stempniewicz N; Keating S; Rowan CG
    Diabetes Obes Metab; 2017 Aug; 19(8):1184-1187. PubMed ID: 28266807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-related nonadherence in the Medicare program: the impact of Part D.
    Kennedy JJ; Maciejewski M; Liu D; Blodgett E
    Med Care; 2011 May; 49(5):522-6. PubMed ID: 21430574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication use and adherence among elderly Medicare beneficiaries with diabetes enrolled in Part D and retiree health plans.
    Stuart B; Simoni-Wastila L; Yin X; Davidoff A; Zuckerman IH; Doshi J
    Med Care; 2011 May; 49(5):511-5. PubMed ID: 21422956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myopic and Forward Looking Behavior in Branded Oral Anti-Diabetic Medication Consumption: An Example from Medicare Part D.
    Sacks NC; Burgess JF; Cabral HJ; Pizer SD
    Health Econ; 2017 Jun; 26(6):753-764. PubMed ID: 27150938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study.
    Yang Y; Thumula V; Pace PF; Banahan BF; Wilkin NE; Lobb WB
    Clin Ther; 2009 Oct; 31(10):2178-88; discussion 2150-1. PubMed ID: 19922889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mail-order pharmacy use and medication adherence among Medicare Part D beneficiaries with diabetes.
    Zhang L; Zakharyan A; Stockl KM; Harada AS; Curtis BS; Solow BK
    J Med Econ; 2011; 14(5):562-7. PubMed ID: 21728913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of coverage gap reform on adherence to diabetes medications.
    Zeng F; Patel BV; Brunetti L
    Am J Manag Care; 2013 Apr; 19(4):308-16. PubMed ID: 23725362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of diet alone, insulin, sulfonylureas, metformin, and thiazolidinediones with the severity of coronary artery disease in patients with diabetes mellitus.
    Ravipati G; Aronow WS; Ahn C; Sujata K; Saulle LN; Channamsetty V; Weiss MB
    Am J Ther; 2006; 13(5):400-3. PubMed ID: 16988534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National assessment of Medicare prescription plan coverage gaps among patients with atrial fibrillation in the US.
    Kim MH; Lin J; Kreilick C
    Adv Ther; 2009 Aug; 26(8):784-94. PubMed ID: 19690820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence with biologic therapies in the Medicare coverage gap.
    Tamariz L; Uribe CL; Luo J; Hanna JW; Ball DE; Krohn K; Meadows ES
    Am J Manag Care; 2011 Nov; 17(11):753-9. PubMed ID: 22084895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in the prescription and cost of diabetic medications and monitoring equipment in England 1991-2004.
    Patel H; Srishanmuganathan J; Car J; Majeed A
    J Public Health (Oxf); 2007 Mar; 29(1):48-52. PubMed ID: 17124257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost sharing, adherence, and health outcomes in patients with diabetes.
    Gibson TB; Song X; Alemayehu B; Wang SS; Waddell JL; Bouchard JR; Forma F
    Am J Manag Care; 2010 Aug; 16(8):589-600. PubMed ID: 20712392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.